STOCK TITAN

RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Welcome to our dedicated page for RELIEF THERAPEUTICS HLDG news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on RELIEF THERAPEUTICS HLDG stock.

RELIEF THERAPEUTICS Holding SA, traded as RLFTF, is a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unmet, and rare diseases. The company focuses on advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit patients. Relief Therapeutics offers a diversified portfolio of marketed products, proprietary platform technologies, and a targeted clinical development pipeline. With a mission to provide therapeutic relief to those suffering from rare diseases, Relief Therapeutics is led by an experienced team of industry leaders. Headquartered in Geneva, the company is listed on the SIX Swiss Exchange and quoted on the OTCQB.

Rhea-AI Summary

Relief Therapeutics announced its half-year results for 2022, reporting revenues of CHF 3.24 million from product sales, licensing fees, and royalties. The company anticipates the U.S. launch of PKU GOLIKE in Q4 2022, following the acquisition of commercialization rights for a new dosage form of a prescription drug for PKU. The FDA accepted the NDA for ACER-001 with a decision expected by January 15, 2023. However, the company incurred a net loss of CHF 26.5 million, driven by increased expenses and an impairment charge of CHF 8.2 million on intangible assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics, a Swiss biopharmaceutical company focused on rare diseases, announced participation in the 22nd Annual Biotech in Europe Forum on September 21-22, 2022, in Basel, Switzerland. CFO Jack Weinstein will lead a panel discussion titled Navigating Global Capital Markets in Current Times on September 21 at 1:35 pm CEST, followed by a company presentation at 3:20 pm CEST. The company engages with institutional investors and offers one-on-one meetings during the event. Relief develops innovative treatments for conditions like PKU and pulmonary disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.38%
Tags
conferences
-
Rhea-AI Summary

Relief Therapeutics announced that Jack Weinstein, the Chief Financial Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference scheduled for September 13, 2022, at 1:30 PM ET. The event runs from September 12-14, 2022, where management will conduct one-on-one meetings with registered institutional investors. A live webcast of the presentation will be available on Relief’s website and archived for 90 days. Relief focuses on developing treatments for rare diseases and has ongoing collaborations and product pipelines addressing significant unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
Rhea-AI Summary

Relief Therapeutics has filed a Registration Statement on Form F-1 with the U.S. SEC for a proposed offering of its ordinary shares as American Depositary Shares (ADSs). The details including the number of ADSs and pricing are yet to be determined. Relief aims to list its ADSs on the NASDAQ under the symbol RLFT. However, completion of the offering and listing success are uncertain. Relief operates in rare diseases and has a collaboration with Acer Therapeutics for metabolic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding SA and NRx Pharmaceuticals announced a tentative settlement regarding their pending litigation. The parties will collaborate to finalize this settlement within 30 days and have agreed to a 60-day extension to negotiate the definitive settlement agreement. The settlement may involve a re-allocation of development rights and licensing for aviptadil, although success is not guaranteed. Investors are advised that uncertainties remain regarding the completion of the settlement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics has appointed David McCullough as the Senior Director and Head of U.S. Market Access, effective August 22, 2022. This newly created role is aimed at enhancing market access strategies for the company's products. McCullough brings over 20 years of experience from various biopharmaceutical companies, including Mirum Pharmaceuticals and Novartis Gene Therapies. His expertise will be pivotal as Relief prepares for the October 2022 launch of PKU GOLIKE. This appointment signifies a milestone in Relief's growth and commitment to patient access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary

Relief Therapeutics announced promising three-month stability data for a new formulation of RLF-100 (aviptadil), indicating it may have clinical use for rare lung diseases. The formulation shows potential for stability during shipping and long-term storage. Relief plans to file for additional patent protection and initiate a phase 2b study for pulmonary sarcoidosis in 2023. The FDA pre-IND meeting will confirm efficacy and safety. RLF-100 has a history of safe use in various conditions, with ongoing development for multiple lung diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced that the U.S. SEC has declared effective its Registration Statement on Form 20-F, allowing the company to become a reporting entity under the Securities Exchange Act. This move is part of an effort to list its ADRs on the NASDAQ. While the company plans to file its application soon, success is contingent on meeting listing requirements and receiving NASDAQ approval. The company will not receive proceeds from the ADR program at this stage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced that its partner, Acer Therapeutics, has resubmitted the New Drug Application (NDA) for ACER-001 to the FDA for treating urea cycle disorders (UCDs). This resubmission addresses issues raised in the previous Complete Response Letter (CRL) issued in June 2022, primarily concerning the inspection of a third-party contract packaging facility. Relief notes that Acer believes no other approvability issues remain. The FDA has already provided orphan drug designation for ACER-001, a sodium phenylbutyrate formulation under development for UCDs and Maple Syrup Urine Disease (MSUD).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
none
Rhea-AI Summary

Relief Therapeutics has appointed Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine, effective July 18, 2022. This strategic move aims to advance the company's initiatives in genetic medicine, particularly focusing on developing therapies for rare diseases. Dr. Forte's extensive experience in gene therapy, including leadership roles at Krystal Biotech and PTC Therapeutics, is expected to enhance Relief's commercial and medical strategies. The company aims to leverage Dr. Forte's expertise to evaluate prospective assets in this new field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
management

FAQ

What is the current stock price of RELIEF THERAPEUTICS HLDG (RLFTF)?

The current stock price of RELIEF THERAPEUTICS HLDG (RLFTF) is $4.65 as of December 20, 2024.

What is the market cap of RELIEF THERAPEUTICS HLDG (RLFTF)?

The market cap of RELIEF THERAPEUTICS HLDG (RLFTF) is approximately 55.1M.

What does RELIEF THERAPEUTICS Holding SA do?

RELIEF THERAPEUTICS Holding SA is a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unmet, and rare diseases.

Where is RELIEF THERAPEUTICS Holding SA headquartered?

RELIEF THERAPEUTICS Holding SA is headquartered in Geneva.

On which stock exchanges is RELIEF THERAPEUTICS Holding SA listed?

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.

What is the mission of RELIEF THERAPEUTICS Holding SA?

The mission of RELIEF THERAPEUTICS Holding SA is to provide therapeutic relief to those suffering from rare diseases.

Who leads RELIEF THERAPEUTICS Holding SA?

RELIEF THERAPEUTICS Holding SA is led by an international team of well-established, experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

What are the core therapeutic areas of focus for RELIEF THERAPEUTICS Holding SA?

RELIEF THERAPEUTICS Holding SA focuses on rare skin diseases, rare metabolic disorders, and rare respiratory diseases.

How can I learn more about RELIEF THERAPEUTICS Holding SA?

For more information about RELIEF THERAPEUTICS Holding SA, please visit their website at www.relieftherapeutics.com or follow them on LinkedIn.

RELIEF THERAPEUTICS HLDG

OTC:RLFTF

RLFTF Rankings

RLFTF Stock Data

55.05M
9.65M
27.02%
Biotechnology
Healthcare
Link
United States of America
Geneva